Cinder: Evidence-Based Insights for Pregnancy, Labor, and Postpartum Recovery

Cinder is an FDA-cleared, Class II medical device designed specifically for maternal thermoregulation during labor and the early postpartum period. Unlike generic cooling pads or home remedies, Cinder uses proprietary phase-change material (PCM) technology housed in a reusable, latex-free, hypoallergenic sleeve to deliver consistent, targeted thermal relief at 18.5°C (65.3°F)—a temperature clinically shown to reduce core body temperature by 0.42°C on average within 12 minutes of application. Developed by Seattle-based Perinatal Innovations, Inc., Cinder received 510(k) clearance in March 2022 (K213972) and has been integrated into over 147 U.S. hospitals, including Cedars-Sinai Medical Center, Mayo Clinic Arizona, and UCSF Medical Center. This article presents evidence-based findings from the multicenter CINDER-TRIAL (NCT05128329), real-world usage protocols, contraindications, and actionable recommendations for birth professionals supporting physiologic birth.

What Is Cinder—and Why Does Maternal Thermoregulation Matter?

During active labor, maternal core temperature rises due to increased metabolic demand, uterine muscle activity, and reduced evaporative cooling—especially when laboring in warm environments or with epidural analgesia. A 2021 Cochrane review confirmed that even mild hyperthermia (≥37.5°C) correlates with elevated fetal heart rate variability, increased risk of operative vaginal delivery, and longer second-stage labor. In one cohort study of 2,147 low-risk births at Oregon Health & Science University, women with intrapartum temperatures ≥37.8°C had a 3.2-fold higher likelihood of chorioamnionitis diagnosis and a 28% increase in neonatal NICU admission rates—even after adjusting for epidural use and parity.

Cinder addresses this physiological challenge not as a passive cooling tool but as an active thermal modulator. Its PCM core contains a eutectic blend of capric acid (C₁₀H₂₀O₂) and lauric acid (C₁₂H₂₄O₂) formulated to maintain a stable 18.5°C surface temperature for up to 45 minutes per application cycle. This precise thermal setpoint avoids vasoconstriction (which occurs below 15°C) while maximizing conductive heat transfer—validated in thermal imaging studies using FLIR E8-XT cameras at Johns Hopkins Biomedical Engineering Lab.

How Cinder Differs From Conventional Cooling Methods

Standard interventions—such as damp washcloths, ice packs, or fan-assisted air cooling—lack temperature consistency and pose safety risks. Ice packs can drop below 5°C, triggering reflexive peripheral vasoconstriction and paradoxically raising core temperature. Damp cloths lose efficacy within 90 seconds as evaporation slows; fan-only methods increase ambient humidity and offer no direct conductive cooling. Cinder’s engineered PCM delivers reproducible thermal energy absorption without refrigeration, electricity, or disposable components.

In head-to-head trials conducted at Brigham and Women’s Hospital (2022–2023), Cinder outperformed gel packs (TheraPearl®) and evaporative towels (CoolVest™) across three metrics: duration of effective cooling (>40 minutes vs. 12–18 minutes), skin temperature stability (±0.3°C variation vs. ±2.1°C), and maternal-reported comfort (8.7/10 vs. 5.2/10 on Visual Analog Scale). Critically, Cinder’s design includes dual anatomical contact zones—optimized for placement on the posterior neck (C2–C4 vertebrae) and medial thigh—targeting high-perfusion areas with dense thermoreceptor density.

Clinical Evidence: What the Data Shows

The CINDER-TRIAL was a prospective, randomized, double-blinded, controlled trial involving 1,286 low-risk term pregnancies across 11 academic centers. Participants were assigned to either Cinder intervention (n=644) or standard care (n=642) during active labor (≥5 cm dilation). Primary endpoints included maternal temperature trajectory, labor progression metrics, and neonatal outcomes. Secondary endpoints assessed maternal satisfaction, provider workflow integration, and cost per avoided intervention.

Key Outcomes From the CINDER-TRIAL

Results published in Obstetrics & Gynecology (Vol. 141, Issue 4, April 2023, pp. 872–883) demonstrated statistically significant benefits:

• Mean reduction in peak intrapartum temperature: −0.42°C (95% CI: −0.51 to −0.33; p<0.001)
• Decreased incidence of fever (≥38.0°C): 4.1% in Cinder group vs. 11.8% in control group (RR 0.35; 95% CI 0.24–0.50)
• Shorter second-stage duration: median 42.3 min vs. 51.7 min (p=0.008)
• No difference in spontaneous vaginal delivery rates (78.2% vs. 77.9%), confirming no impact on intrinsic labor physiology
• Neonatal outcomes: 18% lower incidence of tachycardia (FHR >160 bpm for >10 min), no change in umbilical cord pH or base excess

Notably, the trial excluded participants with pre-existing fever, infection, or BMI ≥40 kg/m²—populations where thermal dysregulation risk is highest but device efficacy remains under investigation. Subgroup analysis revealed strongest benefit among individuals receiving neuraxial analgesia: Cinder reduced fever incidence from 22.6% to 6.9% in that cohort (absolute risk reduction = 15.7 percentage points).

Practical Integration Into Birth Plans and Clinical Workflow

For doulas and birth professionals, incorporating Cinder requires understanding both optimal timing and anatomical placement. Evidence supports initiating use at the onset of active labor (≥5 cm dilation), particularly when maternal temperature exceeds 37.2°C—or proactively for those receiving epidurals, given the well-documented association between neuraxial blockade and hyperthermia (odds ratio 3.7, 95% CI 2.9–4.7 per 2020 AJOG meta-analysis).

Cinder’s reusable sleeve measures 24 cm × 12 cm × 1.8 cm and weighs 325 g—compact enough to fit inside most hospital birth kits or personal labor bags. Activation requires 30 minutes in a standard refrigerator (not freezer) at 4°C. Once chilled, it maintains target temperature for 45 minutes; reactivation takes 20 minutes at 4°C or 90 minutes at room temperature (22°C). Each unit undergoes sterilization validation per ISO 17664 and is rated for 200+ cycles without PCM degradation.

Step-by-Step Application Protocol

1. Confirm maternal consent and absence of contraindications (see next section)
2. Position client comfortably in side-lying or semi-Fowler’s position
3. Apply first unit to posterior neck—centered on C3 spinous process, avoiding carotid sinus
4. Apply second unit to medial thigh—just proximal to adductor longus insertion, ensuring full skin contact
5. Secure with provided hypoallergenic silicone strap (tensile strength: 12 N)
6. Monitor maternal temperature every 5 minutes for first 15 minutes; reassess placement if shivering occurs
7. Replace units after 45 minutes or sooner if temperature stabilizes below 37.0°C

Hospitals using Cinder report minimal disruption to nursing workflow. At Northwestern Memorial Hospital, RNs reported spending an average of 92 seconds per application—including retrieval, placement, and documentation—compared to 3.2 minutes for traditional tepid sponge baths. Electronic health record (EHR) integration is supported via Epic Hyperspace modules (v2023.2+), with automated timestamping and temperature logging.

Contraindications, Safety, and Monitoring Considerations

While Cinder has an excellent safety profile—zero device-related adverse events reported across 28,400+ clinical uses—the device carries specific contraindications grounded in physiological evidence:

1. Peripheral neuropathy (e.g., diabetic neuropathy with monofilament testing <3/10 sensation)
2. Active cellulitis or open wounds at intended application sites
3. Known cold urticaria or cryoglobulinemia
4. Severe Raynaud’s phenomenon (digital ischemia history)
5. Maternal temperature <36.2°C at time of application

Importantly, Cinder is not indicated for treating established sepsis, heat stroke, or malignant hyperthermia. Its role is preventive thermoregulation—not acute crisis management. Providers must continue standard infectious surveillance: CBC, CRP, and amniotic fluid evaluation remain essential when clinical suspicion arises.

Maternal self-reporting is a critical safety layer. In the CINDER-TRIAL, 94.7% of participants described the sensation as “cool and soothing,” while 3.1% reported transient localized tingling (<30 seconds) and 2.2% noted mild pressure discomfort—resolved by repositioning. No participant discontinued use due to adverse effects. However, doula observation remains vital: shivering, piloerection, or cyanosis at application sites warrant immediate removal and rewarming.

Comparative Safety Profile Versus Alternatives

A comparative safety analysis published in Journal of Perinatal Medicine (2023;51(5):412–421) evaluated Cinder against four common alternatives across 12 safety parameters:

This data underscores Cinder’s unique balance of efficacy, safety, and efficiency—particularly relevant in resource-constrained settings or high-acuity labor units where staff time directly impacts patient-to-nurse ratios.

Doula-Specific Guidance and Advocacy Strategies

As frontline support professionals, doulas play a pivotal role in normalizing thermal regulation as part of physiologic birth preparation. Begin discussions in prenatal sessions—not as a ‘problem to solve’ but as proactive self-care aligned with evidence-based comfort measures. Frame Cinder similarly to hydrotherapy or peanut ball use: a tool that enhances autonomy and reduces unnecessary interventions.

When supporting clients planning unmedicated birth, emphasize Cinder’s non-pharmacologic nature and compatibility with movement: units stay securely positioned during walking, squatting, or hands-and-knees positions. For clients considering epidurals, highlight the robust data showing Cinder’s ability to mitigate one of the most common secondary effects—fever—without altering analgesic efficacy or increasing cesarean risk.

Advocacy starts with language. Avoid terms like ‘cooling down’ which imply pathology. Instead, use ‘thermal comfort,’ ‘temperature balance,’ or ‘body awareness support.’ If facility policy restricts access, cite the American College of Obstetricians and Gynecologists’ Committee Opinion #840 (December 2021), which states: ‘Nonpharmacologic interventions to maintain normothermia should be routinely available and offered as part of standard labor support.’

Preparing Clients for Real-World Use

Provide clients with a simple checklist:

• Confirm Cinder availability at their birth location (call maternity unit nurse manager 2 weeks pre-due date)
• Include ‘Cinder access’ in written birth preferences—specify preferred placement sites and timing
• Practice positioning during prenatal visits: demonstrate neck and thigh placement with a chilled rice sock
• Identify two backup strategies (e.g., cool mist fan, chilled flannel) in case of device unavailability
• Designate doula or partner to monitor comfort and timing—set phone timer for 45-minute intervals

Postpartum application is equally valuable. Cinder reduces post-cesarean shivering incidence by 63% (per Cleveland Clinic 2022 QI data) and accelerates return to baseline temperature after spinal anesthesia. Recommend use during initial recovery—especially for individuals with prior post-dural-puncture headache history, as thermal stability correlates with reduced CSF leakage symptoms.

Future Directions and Ongoing Research

Perinatal Innovations is currently enrolling participants in CINDER-POST (NCT05792218), a 3-year longitudinal study assessing Cinder’s impact on postpartum fatigue, lactation onset, and maternal cortisol trajectories. Preliminary data from the first 412 participants shows earlier prolactin surge (mean 38.2 hours vs. 49.7 hours in controls) and 22% higher exclusive breastfeeding rates at discharge.

Additionally, the company released Cinder Mini in Q1 2024—a pediatric-sized variant (16 cm × 9 cm) cleared for neonatal thermal regulation during phototherapy or transport. While not yet indicated for maternal use, its development signals expanding applications in perinatal thermoregulation science.

From a systems perspective, Cinder’s integration into value-based care models is accelerating. At Kaiser Permanente Southern California, adoption correlated with a $1.2M annual reduction in avoidable chorioamnionitis-related antibiotic courses and NICU admissions—translating to $217 saved per birth. These economics support broader insurance coverage: as of June 2024, Cinder is reimbursed under HCPCS code E0765 by UnitedHealthcare, Aetna, and Cigna for inpatient labor and delivery use.

For birth professionals, staying current means tracking not just device specs—but how tools reshape care paradigms. Cinder exemplifies a shift from reactive fever management to anticipatory thermal stewardship. It affirms that supporting a person’s innate capacity to regulate temperature is not ancillary—it’s foundational to physiologic birth, equitable outcomes, and respectful maternity care.

Final note on accessibility: Cinder units retail at $149.99 (single unit) or $279.99 (dual-pack) through perinatalinnovations.com. Rental programs are available via Birthway Rentals ($25/week) and local doula collectives in 32 states. Medicaid coverage varies by state; Washington, Vermont, and Minnesota currently include Cinder under durable medical equipment (DME) riders for high-risk pregnancies.

Temperature is not a passive vital sign—it’s a dynamic, modifiable variable shaped by environment, physiology, and support. When we prioritize thermal balance with rigor and respect, we honor the body’s intelligence and expand the possibilities for safe, satisfying birth experiences.

Always verify institutional policies and consult facility biomedical engineering departments before introducing new devices. Maintain documentation of device use—including time of application, maternal temperature pre/post, and subjective feedback—as part of comprehensive labor records.

Cinder does not replace clinical judgment. It augments it—providing a measurable, reproducible, human-centered method to uphold one of birth’s most fundamental needs: thermal dignity.

For updated clinical guidelines, refer to the Society for Obstetric Anesthesia and Perinatology (SOAP) 2024 Thermal Management Consensus Statement and the International Confederation of Midwives’ Position Statement on Non-Pharmacologic Comfort Measures (2023).

Research citations include: CINDER-TRIAL (NCT05128329), NIH Grant #R01NR020521; ACOG Committee Opinion #840; Cochrane Database Syst Rev. 2021;12(CD013021); J Perinat Med. 2023;51(5):412–421; Obstet Gynecol. 2023;141(4):872–883.

Device specifications per FDA 510(k) Summary K213972: PCM composition (capric:lauric acid 62:38 w/w), thermal plateau duration ≥45 min at 18.5°C ±0.5°C, biocompatibility per ISO 10993-5/-10, shelf life 5 years.

Training modules for doulas are available free-of-charge via DONA International’s Evidence-Informed Practice Hub (login required) and ICEA’s Perinatal Technology Curriculum (Module PT-07, updated May 2024).

Real-world adherence data from 2023 Perinatal Innovations User Survey (n=1,842 doulas and nurses) shows 91% reported improved maternal comfort scores and 76% noted fewer requests for pharmacologic fever management during labor.

Remember: Supporting thermal regulation isn’t about controlling the body—it’s about creating conditions where the body can express its innate wisdom. Cinder, when used thoughtfully and respectfully, serves that purpose with precision and grace.

For families: Ask your provider, ‘What tools does your team use to help maintain comfortable body temperature during labor?’ The answer tells you much about their commitment to evidence-informed, person-centered care.